secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001104659-25-055990
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa shareholders elect all director nominees and approve all 13 proposals at annual meeting
--------------------------------------------------------------------------------

- All 10 director nominees elected; Stephen R. Biggar received 15.3M against votes, Felix J. Baker 12.3M against.
- Say-on-pay (Prop 10) passed with 49.1M for, 550.7K against.
- Authority to allot shares up to ~35% of share capital (Prop 11) passed: 41.2M for, 11.2M against.
- Disapplication of pre-emption rights (Prop 12) passed: 40.7M for, 11.7M against.
- Preference share redemption to create distributable reserves (Prop 13) passed with 52.4M for, 23.2K against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925055990/0001104659-25-055990-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925055990/tm2517053d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-055990

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer